To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Select year:
Handouts
Downloadable resources with key insights and clinical trial updates.
Congenital Myasthenic Syndrome (CMS) Disease State Handout
A summary of congenital myasthenic syndrome (CMS). It covers clinical symptoms of CMS, CMS subtypes impacting acetylcholine receptor (AChR) clustering, disease burden and proposed pathophysiology.
Congenital Myasthenic Syndrome (CMS) vs. congenital myopathy
A summary of Congenital Myasthenic Syndrome (CMS) highlighting the clinical suspicion of CMS vs. congenital myopathy, a common misdiagnosis.
Congenital Myasthenic Syndrome (CMS) vs. myasthenia gravis
A summary of Congenital Myasthenic Syndrome (CMS) highlighting the clinical suspicion of CMS vs. myasthenia gravis, a common misdiagnosis.
Congenital Myasthenic Syndrome (CMS) vs. muscular dystrophy
A summary of Congenital Myasthenic Syndrome (CMS) highlighting the clinical suspicion of CMS vs. muscular dystrophy, a common misdiagnosis.
Empasiprubart Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): emnergize & emvigorate Trial Awareness Handout
An overview of of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), including the proposed mode of action of empasiprubart, and overview of the inclusion/exclusion criteria and study designs of the emnergize and emvigorate clinical trials.
argenx Pipeline Handout
A summary of the argenx investigational pipeline.
Multifocal Motor Neuropathy (MMN) Disease State Education Handout
A summary of Multifocal Motor Neuropathy (MMN), covering the disease state of MMN and the involvement of complement activation.
VYVGART/VYVGART HYTRULO: generalized myasthenia gravis (gMG) and Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Cross-Indication Safety Neurology Congress Handout
An overview of the key neurology indication data reported in the publication "Safety Profile of Efgartigimod From Global Clinical Trials Across Multiple IgG-Mediated Autoimmune Diseases," published in Gwathmey et al. Expert Rev Clin Immunol. 2025;21(5):627–638. It will be provided proactively to healthcare professionals at neurology congresses to inform on the cross-indication safety of both efgartigimod and efgartigimod rHuPH20 SC.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Compass Study Clinician Flyer
A flyer for referring patients to argenx-Folia Health real-world evidence Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Compass Study. This study is enrolling patients with CIDP who are not on Vyvgart Hytrulo to collect longitudinal, patient- and caregiver-generated data on the everyday burden and experience of living with CIDP.
Poster/oral presentations 2026
AANEM posters will be available following their presentation at the congress.
Videos
A collection of videos showcasing recent developments and expert
insights from AANEM.
Richard’s perspective – Living with MMN
This video interview between Lisa Butler and Richard Sperry from the CIDP/GBS Foundation (US) describes Richard’s experience with MMN.
Brenda’s Multifocal Motor Neuropathy (MMN) Story
Brenda shares her experience living with MMN.
Idiopathic Inflammatory Myopathies (Myositis), Disease Pathogenesis
This mechanism of disease video details myositis; a systemic auto-immune rheumatic disease.
Efgartigimod, Mechanism of Action
This video illustrates efgartigimod’s differentiated mechanism of action.
Handouts
Downloadable resources with key insights and clinical trial updates.
ADHERE REAL Study Flyer
Awareness flyer for the ADHERE REAL study.
Empasiprubart MMN Card
Awareness flyer for the Empassion study.
ALS clinical study card
Awareness flyer for the ALS study
ALKIVIA clinical study card
Awareness flyer for the ALKIVIA study.
VYVGART Pregnancy study
Awareness flyer for the VYVGART Pregnancy study.
ADAPT OCULUS clinical study card
Awareness flyer for the ADAPT Oculus study.
Immunology Innovation Program flyer
This flyer contains information about argenx’s commitment to developing antibodies against novel targets through co-creation.
MMN Disease State Handout
This handout discusses disease state education around MMN including symptoms, disease burden, and pathophysiology.
Myositis Disease State Handout
This handout discusses disease state education around Myositis.
Efgartigimod Mechanism of Action Handout
This handout discusses efgartigimod and its proposed mechanism of action, not specific to a disease state.
ADAPT Oculus Study handout
argenx pipeline handout
This handout showcases argenx’s pipeline.
argenx Medical Affairs: Science of Collaboration Congress Handout
Empasiprubart 117 Proposed Mechanism of Action Handout
This handout discusses empasiprubart and its proposed mechanism of action, not specific to a disease state.
Poster/oral presentations 2025
Recent developments in the neuromuscular field.
Poster/oral presentations 2024
Recent developments in the neuromuscular field.
We couldnot find any results for your search.
Please consider trying a different term.
Items per page:
- 3
- 6
- 9
- 12
1-12 of 16
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2026 argenx MED-US-NON-2600280 v1 09/2026. All Rights Reserved.